US patents: mandatory US counsel from July 2026

What actually changes on 20 July 2026?

Beginning Monday, 20 July 2026, patent applicants and patent owners not domiciled in the United States or its territories are required to be represented by a USPTO registered patent practitioner, and where representation is required under the new rule, papers submitted to the USPTO must be signed by a USPTO registered patent practitioner.

Those two sentences carry the whole operational load. The first creates a status requirement — representation. The second converts that status into a mechanical test at the point of filing: whose name is on the signature line. For a Swiss company that has been prosecuting its own US cases with an in-house signatory, or that has let a European or Ukrainian representative sign US papers directly, the change is not a matter of strategy or drafting style. It is a question of whether the next document the office receives is signed by someone whose signature the office will now accept.

The practical consequence is that signature authority, not filing strategy, is the thing to audit first. If your docketing system records who signs US papers — and many do not, because it has never mattered — that field is now the one that determines whether a response lands or bounces.

Does this only affect applications filed after that date?

No: the new representation requirement applies to all papers received in patent matters on or after 20 July 2026, regardless of the filing date of the application.

This is the detail most likely to be missed by portfolio managers who read the headline and assume a grandfathering rule. There is none in the notice. A US application filed in 2019, or a patent granted in 2016, is in scope for any paper received on or after the cut-off date. The reference point is receipt by the office, not the date the application was filed and not, on the face of the notice, the date you posted or uploaded the paper.

For anyone running a US portfolio from Europe, that reframes the exercise. The question is not “which of my new filings need US counsel”, it is “which of my existing files will generate a paper after 20 July 2026” — and for an active portfolio the answer is close to all of them.

How much lead time does the office expect?

The USPTO advises foreign-domiciled applicants and patent owners to obtain representation well in advance of any currently pending time period for response.

That advice is worth reading as more than politeness. Appointing a practitioner is not instantaneous: there is conflict clearance, engagement, a power of attorney to execute and file, and a period during which correspondence records are updated. If a response period is already running and expires shortly after 20 July 2026, the sequence has to be started now rather than treated as part of preparing the response itself.

The notice does not describe any transition arrangement or grace period for response deadlines that are already pending when the requirement takes effect. In the absence of one, the safe planning assumption is that there is not one, and that a paper arriving on 21 July 2026 is judged by the rule in force on the day it arrives.

Why is the USPTO doing this?

The USPTO describes the requirement as part of its efforts to improve efficiency, reduce the backlog, improve quality, and deter fraud and misrepresentation in patent matters.

The stated rationale matters chiefly because it signals the office’s likely attitude to enforcement. A measure framed around fraud deterrence and file quality is unlikely to be administered leniently in its early months, and the categories of filing most associated with irregular unrepresented practice are the ones where scrutiny should be expected to be firmest. In-house counsel who have been signing their own US papers competently for years are caught by a rule that was not written with them in mind, which does not make them any less caught.

Is the USPTO now an outlier, or catching up?

The USPTO states that the requirement brings its policies in line with most other countries, including Japan and the European Patent Office, which require such parties to be represented by a licensed or registered person of that country or office for most filings.

European readers will recognise the pattern immediately, because they administer the other side of it: a US applicant before the EPO is already in the position that a Swiss applicant will occupy before the USPTO. That familiarity is useful. The internal processes your organisation already runs for appointing local representatives in other jurisdictions — engagement, power of attorney, correspondence address, invoicing — are the processes to reuse here, rather than building something new for the US.

The comparison also tempers any assumption that the requirement is a temporary irritation. Offices that have adopted local-representation rules do not generally reverse them.

What does the USPTO notice not settle?

The alert states the requirement and its start date, and nothing beyond what is set out above; the boundary questions turn on the underlying rule text rather than on this notice.

Be precise about the size of that gap before briefing a board or a business unit. The notice does not define what counts as domicile for a corporate applicant — a point that is far from trivial for a group with a Swiss parent, a US operating subsidiary and inventors employed in Ukraine or Poland. It does not identify which categories of paper, if any, fall outside the requirement: fee payments, maintenance fees, PCT national-phase entry papers, assignment recordations and information disclosure statements are all plausible boundary cases, and none of them is resolved one way or the other by this notice.

It likewise says nothing about whether a foreign patent attorney may remain of record as correspondent while a registered practitioner signs, and nothing about the fate of a paper signed after the cut-off by an unrepresented foreign party — whether such a paper is treated as unsigned, curable, or simply not accorded effect. It addresses patent matters; it says nothing about trademark practice. And, as noted above, it describes no transition or grace period.

Those are not minor drafting omissions. They are the questions that will determine how much work the change actually creates for a given portfolio, and they have to be answered from the rule text, not from the reminder. Any advice you give internally before reading the rule itself should be labelled as provisional.

How do you find a practitioner, and will the office help?

The USPTO maintains a Patent Practitioner Home Page containing a directory of practitioners currently authorised to represent others before the USPTO in patent matters, and the office states that it cannot aid in the selection or recommendation of an attorney or agent.

That division of labour is worth flagging to colleagues who expect the office to point them somewhere. The directory answers one question only — whether a given person is currently authorised — and it is the right tool for verifying that a practitioner your organisation already uses, or a name proposed by a US associate, is in fact registered. Selection remains entirely yours, on the ordinary criteria of technical fit, capacity and cost.

Use the directory as a verification step rather than a sourcing tool: confirm current authorisation for every practitioner you intend to put of record, and do it before, not after, the power of attorney is executed.

What should an IP manager do now?

Audit the US portfolio for signature authority, then work the calendar backwards from 20 July 2026.

Concretely: identify every pending application and granted patent where the person who signs papers is an in-house signatory, a European or Ukrainian representative, or a non-registered agent, and put a USPTO registered practitioner of record before the next response, fee or maintenance deadline on that file. Sort the resulting list by due date and start with the deadlines falling shortly after 20 July 2026, since papers are judged by their receipt date rather than the application’s filing date, and a file that looks comfortable on a filing-date view may be the most exposed.

While the powers of attorney are being prepared, re-check the correspondence records on each file so that office communications are not sent to an address that no longer reaches the right person. A change of representative is also a change in the path your incoming correspondence takes, and a missed office action is a worse outcome than a late-appointed practitioner. Finally, read the underlying rule text before deciding that any category of filing — fee payments, national-phase entries, assignments — sits outside the requirement, because this notice does not tell you that it does.